DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Shukra Pharmaceuticals Ltd?

Shukra Pharmaceuticals Ltd has a price-to-earnings (PE) ratio of 68.9 in the Healthcare sector.

What is the market capitalisation of Shukra Pharmaceuticals Ltd?

Shukra Pharmaceuticals Ltd has a market capitalisation of approximately ₹1,546 crore.

Shukra Pharmaceuticals Ltd

SHUKRAPHARMACEUTICALSLTD·NSE·Healthcare

₹0.00▲ +0.00 (+0.00%)

⚠️Trading suspended. Not a live price.

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

52W₹17

₹65-35%

Open

—

High

—

Low

—

Prev Close

—

Volume

—

VWAP

—

Snapshot

Key fundamentals

Market Cap

₹1,546 Cr

P/E Ratio

68.90Expensive

P/B Ratio

16.79

EPS

₹0.22

Book Value

₹2.05

ROE

28.90%Strong

ROCE

22.00%Efficient

Dividend Yield

0.03%

Debt / Equity

0.06Low

Face Value

₹1.00

52W High

₹65.26

52W Low

₹17.06

Sector

Healthcare

Industry

Pharmaceuticals

Fairly Valued

Narrow moatHigh uncertainty

Fair value estimate

₹5

No recent traded price

BearFair valueBull

₹2₹5₹14

/100

Business quality — Solid

Growth 50Profitability 100Efficiency 70Valuation 49

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Expensive — trades at 69× earnings

Strengths

Virtually debt-free balance sheet
Strong returns on equity (29%)
Capital is working hard (ROCE 22%)
Promoters hold a controlling stake

Risks

Expensive — trades at 69× earnings

How we got there

Fair value methods

Residual income

15% ROE fading to 12% over ~10 yrs, on ₹2 book

₹2

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹14

Analyst target

No analyst coverage

—

Blended fair value₹5

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Strong returns on equity (29%)
Capital is working hard (ROCE 22%)
Promoters hold a controlling stake

Bear case

Expensive — trades at 69× earnings

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

68.9Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

28.9%Strong

Above 15% is considered healthy for Indian equities

ROCE

22.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.06Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1,546 Cr

P/B

16.79

EPS

₹0.22

Div Yield

0.03%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Expensive

P/E 68.9×

Growth

Shrinking

-1% rev CAGR

Profitability

Excellent

28.9% ROE

Financial health

Rock solid

D/E 0.06

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

-1.3%

+38.8%

10Y

+27.5%

Profit

+70.5%

—

10Y

—

EPS

+249.0%

—

10Y

—

Profile

Pros

Company is almost debt free.
Company is expected to give good quarter
Company has delivered good profit growth of 175% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%

Watch-outs

Cons

Stock is trading at 16.8 times its book value
Debtor days have increased from 122 to 148 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

51%

Promoter

Promoters

51.0%0.00

Public

9.4%-0.06

FII / FPI

0.0%0.00

DII

0.1%0.00

Others

39.6%

Total shareholders

27,173+1,524 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter50.96%

DII0.11%

Public9.37%

Others39.56%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]